MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Novartis AG (NYSE: NVS)*
Organization & Developments: Novartis
*Developments: Novartis
Parents
Organization & Developments: Novartis
Children
*2022, Novartis secured another approval in the treatment Pluvicto for prostate cancer.
*Developments: Novartis (Archives 2010-2016)
*The Swiss pharmaceutical giant won approval in 2018 for a radiopharmaceutical drug called Lutathera for a rare type of cancer in the pancreas and gastrointestinal tract.
2017: Biotech Forum Daily Digest: Trump Dings Biotech, What Now For Conatus Pharmaceuticals? - Conatus Pharmaceuticals (NASDAQ:CNAT)
2017: Can Xencor Continue To Rally? - Xencor, Inc. (NASDAQ:XNCR)
2017: FDA Ad Com unanimously backs Novartis' CAR-T for ALL; shares up 2% - Bellicum Pharmaceuticals (NASDAQ:BLCM)
2017: Has licensing deal for a nonalcoholic steatohepatitis {NASH} candidate under a strategic collaboration with Novartis (NYSE:NVS).
2017: Novartis enter agreement with Conatus for NASH treatment
2017: Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000
2018: Novartis Pushes Its Endocrine Cancer Franchise To The Next Level - Novartis AG (NYSE:NVS)
2018: Senator Wyden, launching probe into Novartis' deal with Cohen, calls contract a 'corporate shakedown'
2018: Spark, Novartis tie up in gene therapy licensing deal worth up to $170M
2019: 8 programs to watch in NASH: Four letters and a multibillion-dollar opportunity
2019: Novartis: A Transformation Story Not To Miss In 2019_seekingalpha.com
2019: UPDATED: Novartis accuses 2 AveXis founders of altering data, stonewalling probe
2020: Novartis bags Mesoblast's stem cell therapy for ARDS, including in Covid-19, in a deal worth up to $1.2B+
2020: Novartis Launches Initiative to Supply COVID-19 Therapies to Low and Middle-Income Countries
2020: Novartis, Siemens to develop blood tests for multiple sclerosis
2020: Novartis, TScan unite on TCR treatments for solid tumors
2020: Propeller's digital inhaler tech to be co-prescribed with Novartis' new asthma med
2022: Novartis AG 2022 Q3 - Results - Earnings Call Presentation_seekingalpha.com
2022: Novartis: Competitors Take Note, Iptacopan Is Coming_ seekingalpha.com
2022: Novartis: Healthy Results_seekingalpha.com
2022: Novartis’s big bet on sickle cell disease struggles to reach Kenya_www.swissinfo.ch
2023: As Novartis pulls back from legacy sickle cell program, Intellia CEO calls the market 'wide open'_fiercebiotech
2023: New And Improved Novartis (NYSE:NVS)
2023: Novartis adds more partners to Beacon of Hope initiative for HBCUs and clinical trial diversity_fiercebiotech
2023: Novartis drug helps stop breast cancer’s return in large study
2023: Novartis to ride with Bicycle in radiopharmaceuticals deal that could cruise to $1.7B
2024: Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation
2024: Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI
2024: Novartis AG 2023 Q4 - Results - Earnings Call Presentation
2024: Novartis And MorphoSys Are A Perfect Match
2024: Novartis inks $1B-plus biobucks deal with Flagship's Generate
2024: Novartis, Ratio sign radiopharmaceutical pact to the tune of $745M biobucks
2024: Novartis: Best Performing Big Pharma Of Past 6 Months Still Looks A Solid Long-Term Bet
2024: Novartis: It's Not Too Late To Buy This Dividend Stock Now
2024: Novartis: Strong Financials, But Market Skepticism Persists Amid Pipeline Concerns
2024: Novartis: Value Continues To Build With Double-Digit Percentage Growth Products_seekingalpha.com
2024: Novartis' Pluvicto expected to dominate prostate cancer radiopharmaceutical market
2024: Novartis’ Lutathera Radiopharma Therapy Improves Survival in Difficult-to-Treat Brain Tumors
2024: This pharma giant’s long list of new drugs should cushion the fall from the ‘patent cliff’
2024: Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
2025: Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025
2025: Why Novartis Remains A 'Buy' After Beating Expectations Again
Jumps
*Organization: Novartis